Clinical Trials
3 trialsNCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05556720 2025-10-03
BOOST-IC
Monash University
Phase 3 Active not recruiting
NCT04761822 2025-08-12
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed